John E Harrison
Overview
Explore the profile of John E Harrison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
585
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Terrera G, Harrison J, Ritchie C, Ritchie K
J Alzheimers Dis
. 2020 Mar;
74(4):1203-1210.
PMID: 32144988
Alterations in Alzheimer's disease (AD) biomarkers have been observed decades before the onset of dementia. Cognitive dysfunction, while central to the clinical diagnosis of AD, has long been considered as...
12.
Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky S, et al.
Alzheimers Res Ther
. 2020 Mar;
12(1):21.
PMID: 32122400
Background: Synapse damage and loss are fundamental to the pathophysiology of Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges...
13.
Sabbagh M, Hendrix S, Harrison J
Alzheimers Dement (N Y)
. 2019 Oct;
5:13-19.
PMID: 31650002
Despite billions of dollars invested in clinical trials to develop novel therapeutics for Alzheimer's disease, no approved treatments have been developed in the past 15 years. In that span, new...
14.
Jutten R, Harrison J, Lee Meeuw Kjoe P, Ingala S, Vreeswijk R, van Deelen R, et al.
Alzheimers Res Ther
. 2019 May;
11(1):45.
PMID: 31092277
Background: The cognitive-functional composite (CFC) was designed to improve the measurement of clinically relevant changes in predementia and early dementia stages. We have previously demonstrated its good test-retest reliability and...
15.
Harrison J
CNS Spectr
. 2019 Mar;
24(1):144-153.
PMID: 30859935
A key message from the review of cognitive dysfunction in psychiatry published by Millan et al (2012) was not just that cognitive skills are often compromised in patients with psychiatric...
16.
Harrison J, Barry H, Baune B, Best M, Bowie C, Cha D, et al.
Int J Methods Psychiatr Res
. 2018 Aug;
27(3):e1736.
PMID: 30088298
Objectives: There is a need for a brief, reliable, valid, and sensitive assessment tool for screening cognitive deficits in patients with Major Depressive Disorders. This paper examines the psychometric characteristics...
17.
Harrison J
Alzheimers Res Ther
. 2018 Jul;
10(1):61.
PMID: 29958538
Background: The FDA have recently published draft guidance for the development of treatments for early Alzheimer's disease. Key features of this guidance are the advocacy of sensitive cognitive measures and...
18.
Pendergrass J, Targum S, Harrison J
Innov Clin Neurosci
. 2018 Mar;
15(1-2):36-44.
PMID: 29497579
This brief review explores the areas of cognitive impairment that have been observed in cancer patients and survivors, the cognitive assessment tools used, and the management of the observed cognitive...
19.
Harvey P, Sabbagh M, Harrison J, Ginsberg H, Chapman M, Manvelian G, et al.
Eur Heart J
. 2017 Nov;
39(5):374-381.
PMID: 29186504
Aims: Despite patient reports of neurocognitive disorders with lipid-lowering treatments (LLTs), large clinical trials have found no significant association between neurocognitive disorders and LLTs. We assessed incidence of neurocognitive treatment-emergent...
20.
Cummings J, Scheltens P, McKeith I, Blesa R, Harrison J, Bertolucci P, et al.
J Alzheimers Dis
. 2016 Oct;
55(3):1131-1139.
PMID: 27767993
Background: Souvenaid® (uridine monophosphate, docosahexaenoic acid, eicosapentaenoic acid, choline, phospholipids, folic acid, vitamins B12, B6, C, and E, and selenium), was developed to support the formation and function of neuronal...